HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT00222235

Glycine or D-cycloserine added to antipsychotic treatment for schizophrenia

About this title

Read the official source —
Medication studyAges 18–54Israel + United States
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 54 years. Other eligibility criteria applied.

Listed locations
Los Angeles and 4 more locationsSee all locations and recruitment
Study phase
Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study clarity

Study information

Study start dateStarted: January 2000
Recruitment status
Completed
Enrollment listed in the registry
240
Sponsor
University of Maryland, Baltimore
Sponsor type
University
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2, Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Locations
United States, Israel
Age range
From 18 Years to 54 Years
Official registry ID
NCT00222235
Official title
Show the full official title

Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST)

Looking for a study you can join?

Explore recruiting studies

Get this study by email

HopeStage may email me about this study.
Loading the security check...

Recruitment & locations

Completed

Los Angeles, United States · Baltimore, United States · Glen Oaks, United States

2 more locations
  • Orangeburg, United States
  • Jerusalem, Israel
Checked Official study record (opens in a new tab)
FAQ

Questions about this study

Who is behind this study?

The study sponsor is University of Maryland, Baltimore, a university.

Did this study involve medication?

Yes. The study involved medication, including d-cycloserine, glycine and placebo.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 54 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies